ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
01 11월 2021 - 8:00PM
Arecor Therapeutics plc(“Arecor”
or the “Group”)
ARECOR
ANNOUNCES AN
EXCLUSIVE
FORMULATION STUDY
COLLABORATION
WITHA LEADING
GLOBAL MEDICAL PRODUCTS COMPANY
TO DEVELOP A STABLE READY TO
ADMINISTER PRODUCT
Cambridge, UK, 1 November 2021:
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group
advancing today’s therapies to enable healthier lives, today
announces that it has signed an exclusive formulation study
collaboration with a leading global medical products company.
Under the terms of the agreement, Arecor will
use its proprietary formulation technology platform, Arestat™, to
develop a differentiated, stable, liquid drug product, for
intravenous administration in two concentrations, that is
Ready-to-Administer (“RTA”). The new liquid formulation of the
product supports safe medication practices and operational
efficiency by eliminating the need for reconstitution. The partner
will fund the development work and has the option to acquire the
rights to the new proprietary formulation and associated
Intellectual Property under a technology licensing model to further
develop and commercialise the product.
Sarah Howell, Chief Executive
Officer of
Arecor,
said: "We are very pleased to
announce this new partnership today, our fourth in the past six
months, showcasing our commercial strategy to drive growth through
our portfolio of collaborations across leading pharmaceutical,
medical products and biotech companies. This collaboration further
demonstrates the strength of our proprietary technology platform,
Arestat™ in developing ready-to-administer (RTA) medicines, which
are becoming increasingly important to enable fast, safe and
effective treatment of patients.”
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)
-ENDS-
For more information, please
contact:
|
Arecor Therapeutics plc |
www.arecor.com |
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060Email: info@arecor.com |
|
|
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060Email: info@arecor.com |
|
|
|
|
Mo Noonan, Communications |
Tel: +44 (0) 7876 444977Email: mo.noonan@arecor.com |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)Rupert Dearden
(Corporate Broking) |
Tel: +44 (0) 20 7886 2500 |
|
|
|
|
Consilium Strategic Communications |
|
|
Chris Gardner, David Daley, Angela Gray |
Tel: +44 (0) 20 3709 5700Email: arecor@consilium-comms.com |
Notes to Editors
About Arecor Arecor
Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat™, we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat™ platform is supported by an extensive patent
portfolio.
For further details please see our website,
www.arecor.com
American Resources (NASDAQ:AREC)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
American Resources (NASDAQ:AREC)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
